KHẢO SÁT TÍNH TOÀN VẸN PHÂN TỬ DNA TỰ DO (CCFDNA) TRONG MÁU Ở BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ

Abstract

Objective: Study the concentration and the integrity of ccfDNA in plasmaand then assess the relation to some characteristics of non-small cell lung cancer (NSCLC) patients. Subjects andmethods: A case-control study with 50 NSCLC patients  and 50 healthy controls without cancers, accompanying systemic autoimmune diseases recruited for the study at the Outpatient Department and Oncology Department of Bac Ninh General Hospital during the period from August 2022 to October 2023. Results: The average concentration of ALU-115 in the blood of cases (81.25±48.36 ng/mL) was significantly higher than that in the control group (8.63±17.89 ng/mL), ALU-247 concentration in cases group (51.75±40.25 ng/mL) was significantly increased in than the control group (2.67±3.39 ng/mL), the ratio of ALU-247/ALU-115 in the cases group (0.65± 0.25) significantly higher than the control group (0.52±0.27). When analyzing the power of diagnostic test using the ROC curve for ALU-247 (AUC=96.692%, p<0.001, Se: 94%, Sp: 96%), ALU-115 (96.8%, p<0.001, Se: 100%, Sp: 86%), ALU-247/ALU-115 ratio (64.12%, p=0.015, Se: 86%, Sp: 46%) all have high power for the detectionof NSCLC disease. Conclusion: Concentrations of  ALU-115, ALU-247 biomarkers, and ALU-247/ALU-115 ratio increased in NSCLC patients and tended to increase with the stage of the disease. These biomarkershad the potential in early diagnosisand treatment of NSCLC